‘Value in Health’, the official journal of ISPOR—which is the specialized society for health economics and results studies, publicized a novel study which showed that medicinal risk-sharing measures can lessen uncertainty relating to the economic impacts of drugs (given that the nature of the arrangement is similar to the setting and sort of uncertainty.
Investigators used the information on management patterns of Dutch non–small cell lung cancer sufferers from 4 hospitals to carry out the analysis aimed at calculating and measuring the expenses and benefits of several risk-sharing arrangements (RSAs). The analysis encompassed 6 types of RSAs :money-back assurance, the continuation of conditional treatment, price related to result, reduced treatment initiation, consumption caps, and fixed expense per every patient.
Mostly RSAs resulted in a decrease in costs to the person paying. But the study shows how the effect on the average total cost per patient can be considerably different between RSAs and in between drug regimens in the same RSA. Moreover, it illustrates how one type of RSA (the conditional treatment continuation) can unfavorably affect results in patients when therapy is stopped prematurely and this leads to a decreased rate of survival inpatient.
“Our research shows that risk-sharing agreements can mitigate uncertainty around the incremental cost-effectiveness or budget impact of drugs,” stated the author MarschaHolleman, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. “However, the choice of whether and which type of RSA to use should depend on a careful analysis of the type of outcomes expected and the type of uncertainty one aims to reduce. If the aim of RSAs is to reduce the risk to the payer, they are most favorable in clinical settings with considerable uncertainty regarding response rates, survival, patient numbers, or any other characteristics that affect budget impact. When these uncertainties do not exist, RSAs lose their value.”
Around the globe, numerous RSAs have been executed over the previous couple of years. Precedingthepresent research, there hasn’t been researching to measure and match the expenses and benefits of other RSAs constructed on real-world data.